Case of Guillain-Barré syndrome following COVID-19 vaccine

Guillain-Barré syndrome (GBS) is a rare immune-mediated disorder of the peripheral nerves. Although its cause is not fully understood, the syndrome often follows infection with a virus or bacteria, although in rare occasions, vaccination may precede GBS. We describe a case of a 62-year-old woman who...

Full description

Saved in:

Bibliographic Details
Published in:	BMJ case reports Vol. 14; no. 6; p. e243629
Main Authors:	Hasan, Tanveer, Khan, Mustafizur, Khan, Farhin, Hamza, Ghanim
Format:	Journal Article
Language:	English
Published:	London BMJ Publishing Group LTD 29-06-2021 BMJ Publishing Group
Subjects:	Antibiotics Back pain Blood pressure Case Report Case reports Coronaviruses COVID-19 vaccines Cytomegalovirus Guillain-Barre syndrome Hepatitis Illnesses Influenza Ostomy Paralysis Patients Peripheral neuropathy Proteins Sepsis Severe acute respiratory syndrome coronavirus 2 Spinal cord Ventilators Zika virus
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Guillain-Barré syndrome (GBS) is a rare immune-mediated disorder of the peripheral nerves. Although its cause is not fully understood, the syndrome often follows infection with a virus or bacteria, although in rare occasions, vaccination may precede GBS. We describe a case of a 62-year-old woman who presented with paraesthesia and progressive weakness of both lower limbs over 3 days. Clinical examination and investigation findings including lumbar puncture and nerve conduction studies were consistent with the diagnosis of GBS. She had no history of either diarrhoea or respiratory tract infections preceding her presentation. However, she had her first intramuscular dose of the Oxford/AstraZeneca COVID-19 vaccine 11 days prior to her presentation. Although no direct link could be ascertained, the purpose of this report is to highlight the incidence and consider this issue while evaluating any case of GBS in the light of the current pandemic and vaccination programme.
Bibliography:	ObjectType-Case Study-2 SourceType-Scholarly Journals-1 ObjectType-Feature-4 content type line 23 ObjectType-Report-1 ObjectType-Article-3
ISSN:	1757-790X 1757-790X
DOI:	10.1136/bcr-2021-243629